Search Results

stage IIC disease, who are at higher risk of recurrence than those with stage IIIA disease, can also be considered for testing. In the randomized COMBI-AD trial, combining the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib demonstrated

when alectinib is used as frontline therapy,” she noted. The 2018 NCCN Guidelines include recommendations for progression on crizotinib, alectinib, Figure 3. Dabrafenib plus trametinib in BRAF V600E–mutant lung cancer. Reprinted from

specific BRAF inhibitor, prompts rapid and often dramatic tumor regression in 50% to 60% of patients with objective RECIST responses, and improves overall survival (OS) compared with cytotoxic chemotherapy. 4 , 5 Dabrafenib, another selective BRAF

dabrafenib at 150 mg twice daily and trametinib at 2 mg daily, with a Karnofsky performance status (KPS) of 50 and an ECOG performance status (PS) of 3. Treatment was complicated by fevers and a rash that responded to steroids. The steroids were titrated to

the optic apparatus. Given the presence of somatic BRAF V600E mutation in the tumor, the patient elected to be treated with neoadjuvant combination BRAF/MEK inhibition with oral dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) in an

received an experimental targeted therapy of dabrafenib and trametinib (BRAF/MEK inhibitors). Overall, the high-grade glioma cohort received a median of one treatment (range 0–4) with a median follow up of 1.2 ± 0.9 years. Conclusion: Understanding the

scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. A Randomized Phase II Study of Single-Agent Dabrafenib (BRAFi) Versus Combination-Regimen Dabrafenib (BRAFi) and

-institutional, randomized phase 2 trial studies how well dabrafenib works with or without trametinib for patients with metastatic thyroid carcinoma. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is

nervous system (CNS) tumors, increasing evidence has suggested that BRAFi therapy may be effective. Preliminary results from a phase I/II study of dabrafenib in relapsed or progressive pediatric BRAF V600E–mutated low-grade gliomas reported an 82

NCCN Dabrafenib and Trametinib Request for Proposals. These grants were made possible through a $4 million research grant from GlaxoSmithKline to scientifically evaluate the clinical effectiveness of dabrafenib (GSK2118436) and trametinib (GSK1120212